TrialHuman vaccines & immunotherapeutics2021

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age.

Brandon Essink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.